TARS Maintains by Jefferies -- Price Target Raised to $105

Barclays reinstated Tarsus Pharmaceuticals (TARS) with an Overweight rating and a $110.00 price target. The company's stock is currently trading at $78.23, with a GF Value™ of $160.86, indicating a 51.4% undervaluation. TARS has a GF Score™ of 46/100, reflecting mixed financial health and performance. The company focuses on biotechnology, particularly eye care, with its lead product being XDEMVY.

Tarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care September 4, 2026 Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a pote

Jefferies raised its price target on Tarsus Pharmaceuticals (NASDAQ:TARS) to $105, citing strong guidance and recent prescription data. The stock has surged 23% in the past week. Tarsus reported Q2 2026 sales of $173.9M, beating expectations, and raised full-year sales guidance for XDEMVY. The company has a market cap of approximately $4B and is considered undervalued by InvestingPro analysis.

Tarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a Phase 3 investigational therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is expected to report topline data in 2029. The acquisition expands Tarsus' pipeline and supports its eye care strategy. TARS shares closed at $83.21 on Thursday, up 0.54%.

Tarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a late-stage oral therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is in a Phase 3 trial with topline data expected in 2029. Tarsus believes ALK-001 could be a blockbuster treatment for this inherited retinal disease with no FDA-approved therapies.

Tarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining rights to ALK-001, a Phase 3 oral treatment for Stargardt disease. ALK-001 has FDA designations and topline data is expected in 2029. The acquisition expands Tarsus' eye care pipeline and leadership, with the company aiming to advance the NORTHSTAR trial.